Impax Laboratories (Nasdaq: IPXL) is expected to report Q1 earnings on May 1. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Impax Laboratories's revenues will expand 0.4% and EPS will decrease -59.6%.

The average estimate for revenue is $129.1 million. On the bottom line, the average EPS estimate is $0.21.

Revenue details
 Last quarter, Impax Laboratories chalked up revenue of $141.1 million. GAAP reported sales were 11% lower than the prior-year quarter's $158.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.30. GAAP EPS of $0.07 for Q4 were 78% lower than the prior-year quarter's $0.32 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 45.5%, 330 basis points worse than the prior-year quarter. Operating margin was 5.7%, much worse than the prior-year quarter. Net margin was 3.4%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $480.2 million. The average EPS estimate is $0.48.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 161 members out of 174 rating the stock outperform, and 13 members rating it underperform. Among 47 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Impax Laboratories a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Impax Laboratories is hold, with an average price target of $25.44.